Literature DB >> 8674031

Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.

B A Carlson1, M M Dubay, E A Sausville, L Brizuela, P J Worland.   

Abstract

Flavopiridol (L86-8275), a N-methylpiperidinyl, chlorophenyl flavone, can inhibit cell cycle progression in either G1 or G2 and is a potent cyclin-dependent kinase (CDK) 1 inhibitor. In this study, we used MCF-7 breast carcinoma cells that are wild type for p53 and pRb positive and contain CDK4-cyclin D1 and MDA-MB-468 breast carcinoma cells that are mutant p53, pRb negative, and lack CDK4-cyclin D1 to investigate the G1 arrest produced by Flavopiridol. Recombinant CDK4-cyclin D1 was inhibited potently by Flavopiridol (Kiapp, 65 nM), competitive with respect to ATP. Surprisingly, CDK4 immunoprecipitates derived from Flavopiridol-treated MCF-7 cells (3 h, 300 nM Flavonolpiridol) had an approximately 3-fold increased kinase activity compared with untreated cells. Cyclin D and CDK4 levels were not different at 3 hr, but cyclin D levels and CDK4 kinase activity decreased thereafter. The phosphorylation state of pRb was shifted from hypercoincident to hypocoincident with the development of G1 arrest. Asynchronous MDA-MB-468 cells were inhibited in cell cycle progression at both G1 and G2 by Flavopiridol. Flavopiridol inhibited the in vitro kinase activity of CDK2 using an immune complex kinase assay (IC50, 100 nM at 400 microM ATP). Immunoprecipitated CDK2 kinase activity from either MCF-7 or MDA-MB-468 cells exposed to Flavopiridol (300 nM) for increasing time showed an initial increased activity (approximately 1.5-fold at 3 h) compared with untreated cells, followed by a loss of kinase activity to immeasurable levels by 24 h. This increased immunoprecipitated kinase activity was dependent on the Flavopiridol concentration added to intact cells and was associated with a reduction of CDK2 tyrosine phosphorylation. Cyclin E and A levels were not altered to the same extent as cyclin D, and neither CDK4 nor CDK2 levels were changed in response to Flavopiridol. Inhibition of the CDK4 and/or CDK2 kinase activity by Flavopiridol can therefore account for the G1 arrest observed after exposure to Flavopiridol.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8674031

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  118 in total

Review 1.  Anticancer drug targets: cell cycle and checkpoint control.

Authors:  G I Shapiro; J W Harper
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

2.  Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation.

Authors:  A Montagnoli; F Fiore; E Eytan; A C Carrano; G F Draetta; A Hershko; M Pagano
Journal:  Genes Dev       Date:  1999-05-01       Impact factor: 11.361

Review 3.  The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer.

Authors:  Katrien Vermeulen; Dirk R Van Bockstaele; Zwi N Berneman
Journal:  Cell Prolif       Date:  2003-06       Impact factor: 6.831

4.  Dietary compounds as potent inhibitors of the signal transducers and activators of transcription (STAT) 3 regulatory network.

Authors:  Anne Trécul; Franck Morceau; Mario Dicato; Marc Diederich
Journal:  Genes Nutr       Date:  2012-01-25       Impact factor: 5.523

5.  ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.

Authors:  Emilia Mahoney; David M Lucas; Sneha V Gupta; Amy J Wagner; Sarah E M Herman; Lisa L Smith; Yuh-Ying Yeh; Leslie Andritsos; Jeffrey A Jones; Joseph M Flynn; Kristie A Blum; Xiaoli Zhang; Amy Lehman; Hui Kong; Metin Gurcan; Michael R Grever; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2012-06-27       Impact factor: 22.113

Review 6.  Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions.

Authors:  Smruthi Vijayaraghavan; Stacy Moulder; Khandan Keyomarsi; Rachel M Layman
Journal:  Target Oncol       Date:  2018-02       Impact factor: 4.493

Review 7.  Selectivity and potency of cyclin-dependent kinase inhibitors.

Authors:  Jayalakshmi Sridhar; Nagaraju Akula; Nagarajan Pattabiraman
Journal:  AAPS J       Date:  2006-03-24       Impact factor: 4.009

8.  Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.

Authors:  Thomas S Lin; Kristie A Blum; Diane Beth Fischer; Sarah M Mitchell; Amy S Ruppert; Pierluigi Porcu; Eric H Kraut; Robert A Baiocchi; Mollie E Moran; Amy J Johnson; Larry J Schaaf; Michael R Grever; John C Byrd
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

9.  Understanding and modulating cyclin-dependent kinase inhibitor specificity: molecular modeling and biochemical evaluation of pyrazolopyrimidinones as CDK2/cyclin A and CDK4/cyclin D1 inhibitors.

Authors:  Karen A Rossi; Jay A Markwalder; Steven P Seitz; Chong-Hwan Chang; Sarah Cox; Michael D Boisclair; Leonardo Brizuela; Stephen L Brenner; Pieter F W Stouten
Journal:  J Comput Aided Mol Des       Date:  2005-02       Impact factor: 3.686

10.  Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig2-positive glioma tumor-initiating cells.

Authors:  Jun Fu; Dimpy Koul; Jun Yao; Shuzhen Wang; Ying Yuan; Howard Colman; Erik P Sulman; Frederick F Lang; W K Alfred Yung
Journal:  Cancer Res       Date:  2013-03-14       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.